Exercise Treatment With Standard Therapy for Metastatic Breast Cancer

Phase 1 Trial of Exercise Treatment With Concurrent First-Line Therapy for Hormone Receptor Positive Metastatic Breast Cancer

This study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that exercise helps delay the development of resistance to hormone therapy while slowing the growth of tumors.

Inclusion Criteria:

• Patients with histologically-confirmed, HR-positive (ER and/or PR), HER2-negative metastatic breast cancer (MBC)
• Postmenopausal status defined by lack of menses for 2 years, oophorectomy, or medical ovarian suppression
• Receiving first line endocrine-based therapy (tamoxifen, aromatase inhibitor, or fulvestrant; concurrent molecular therapy also allowed)
• Sedentary (i.e., <60 minutes / week of exercise)
• Age >18 years
• BMI ≥ 18.5
• Cleared for exercise participation as per screening clearance via PAR-Q+
• Cleared for study participation as per screening consultation with an MSK Exercise Physiologist
• Willingness to comply with all study-related procedures
• Patients with "treated and stable" brain lesions of a duration of ≥ 2 months may be enrolled

Exclusion Criteria:

• Life expectancy <6 months
• Enrollment onto any other therapeutic investigational study
• Mental impairment leading to inability to cooperate
• Concurrent participation in weight loss or other exercise programs